✦ LIBER ✦

Dual tyrosine kinase inhibitors in chronic myeloid leukemia

✍ Scribed by Martinelli, G; Soverini, S; Rosti, G; Baccarani, M

Book ID: 110056470
Publisher: Nature Publishing Group
Year: 2005
Tongue: English
Weight: 322 KB
Volume: 19
Category: Article
ISSN: 0887-6924
DOI: 10.1038/sj.leu.2403950

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Patient adherence to tyrosine kinase inh

Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia

✍ Elias J. Jabbour; Hagop Kantarjian; Lina Eliasson; A. Megan Cornelison; David Ma 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 833 KB

Second-generation tyrosine kinase inhibi

Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia

✍ Ronan Swords; Yesid Alvarado; Jorge Cortes; Francis J. Giles 📂 Article 📅 2007 🏛 Current Science Inc. 🌐 English ⚖ 145 KB

Intolerance to tyrosine kinase inhibitor

Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia : Definitions and clinical implications

✍ Javier Pinilla-Ibarz; Jorge Cortes; Michael J. Mauro 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB

## Abstract Tyrosine kinase inhibitor (TKI) treatment targeting breakpoint cluster region‐Abelson murine leukemia virus, the cause of chronic myeloid leukemia (CML), has revolutionized therapy for patients with this disease. The majority of patients with CML maintain favorable responses with long‐t

Class effects of tyrosine kinase inhibit

Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

✍ Giles, F J; O'Dwyer, M; Swords, R 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 315 KB

Tyrosine kinase inhibitors in acute and

Tyrosine kinase inhibitors in acute and chronic leukemias

✍ Ohanian, Maro; Cortes, Jorge; Kantarjian, Hagop; Jabbour, Elias 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 298 KB

Molecular monitoring in chronic myeloid

Molecular monitoring in chronic myeloid leukemia : Response to tyrosine kinase inhibitors and prognostic implications

✍ Elias Jabbour; Jorge E. Cortes; Hagop M. Kantarjian 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB

## Abstract The majority of patients with chronic‐phase (CP) chronic myeloid leukemia (CML) who are treated with Bcr‐Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve cytogenetic disease remission (ie, Philadelphia chromosome‐positive cells undetectable by cytogenetic evaluation